Thursday 16 October, 2025
Objectives: A system pharmacology model of the circadian clock based on data from rodents has been developed [1] to enable…
Read morePoster: Drug/Disease Modelling - CNS
Longitudinal Parkinson’s Disease Progression Model using Item-Response-Theory Utilized to Predict Treatment Effect of Levodopa
Thursday 16 October, 2025
Objectives: To evaluate and understand the natural history of early and long-term disease progression in Parkinson’s Disease (PD) and to predict…
Read moreA semi-mechanistic model to characterize the pharmacokinetics of orally administered S-Ketamine in healthy human subjects
Thursday 16 October, 2025
Objectives: S-Ketamine is a potent analgesic which can be effectively used in pain management as an adjuvant to enhance analgesia…
Read moreMechanistic model to characterize the pharmacokinetics and -dynamics of subcutaneous dexmedetomidine in healthy adult volunteers
Thursday 16 October, 2025
Objectives: Dexmedetomidine is an α2-adrenoceptor agonist [1] that has been shown to be extremely useful in the management of intractable…
Read moreModel-Based Estimation of Probability of Pharmacological Success for CNS Compounds
Thursday 16 October, 2025
IntroductionAt the early stage of drug development, it’s important to raise a question: what proportion of patients can be expected…
Read moreA population pharmacokinetic model of dense delta-9-tetrahydrocannabinol (THC), 11-OH-THC, and THCCOOH data and its use to estimate daily exposure in an observational cannabis study with sparse data
Thursday 16 October, 2025
Introduction: Population pharmacokinetic (popPK) modeling of delta-9-tetrahydrocannabinol (THC), but not including those of the major metabolites, has been performed in…
Read moreMulticompartmental PKPD model to inform active exposure of nucleic acid therapeutic candidate in CNS disease
Thursday 16 October, 2025
Objectives: Nucleic acid therapeutics, designed to hybridize with target RNAs to modulate gene expression, are promising therapeutic approaches for neurological…
Read moreCNP520 Phase III dose selection support: Identifying the doses producing a desired reduction in CSF Aß-40
Thursday 16 October, 2025
Objectives: One important pathological feature of Alzheimer disease (AD) is the presence of deposits forming amyloid plaques in the brain cortex…
Read moreA PKPD model describing the amyloid precursor protein (APP) derived peptides in subjects receiving CNP520, a BACE-1 inhibitor.
Thursday 16 October, 2025
Objectives: One important pathological feature of Alzheimer disease (AD) is the presence of deposits forming amyloid plaques in the brain…
Read morePopulation pharmacokinetic/pharmacodynamic analysis of multiple nociceptive pain models following a single oral pregabalin dose administration to healthy subjects
Thursday 16 October, 2025
Introduction: Pain models are an objective way to study analgesic effects in addition to the commonly used pain questionnaires in…
Read more